UBS-ETT
Linked to Russell 2000 Net TR Index
Issued by UBS AG, London Branch

Cash settled
SVSP Product Type: Tracker Certificates (1300)
Valor: 23090049; SIX Symbol: ETRUSS

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ff of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA (this paragraph is relevant to public offerings in Switzerland only).

Tax Treatment Switzerland adjusted

1. Description of the Product

Information on Underlying

<table>
<thead>
<tr>
<th>Underlying(s)</th>
<th>Initial Underlying Level</th>
<th>Conversion Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russell 2000 Net TR Index (Bloomberg: RU20N30U Index)</td>
<td>1,508.26</td>
<td>10:1</td>
</tr>
</tbody>
</table>

Index Description

The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe. The Russell 2000 is a subset of the Russell 3000® Index representing approximately 10% of the total market capitalization of that index. It includes approximately 2000 of the smallest securities based on a combination of their market cap and current index membership.

The Russell 2000 Index is constructed to provide a comprehensive and unbiased small-cap barometer and is completely reconstituted annually to ensure larger stocks do not distort the performance and characteristics of the true small-cap opportunity set.

Product Details

<table>
<thead>
<tr>
<th>Security Numbers</th>
<th>Valor 23090049 / ISIN: CH0230900497 / WKN: US0SNU</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIX Symbol</td>
<td>ETRUSS</td>
</tr>
<tr>
<td>Issue Size</td>
<td>Up to 20,000 Units (with reopening clause)</td>
</tr>
<tr>
<td>Issue Price of 1 ETT</td>
<td>USD 150.83 (=100% of the Initial Underlying Level, adjusted by the Conversion Ratio), (unit quotation)</td>
</tr>
<tr>
<td>Management Fee (MF)</td>
<td>0.00% (subject to adjustment)</td>
</tr>
<tr>
<td>Settlement Currency</td>
<td>USD</td>
</tr>
</tbody>
</table>

Dates

| Launch Date                                    | 06 December 2013                               |
| Pricing Date ("Pricing")                      | 06 December 2013                               |
| First SIX Trading Date (anticipated)          | 12 December 2013                               |
| Issue Date / Payment Date                     | 12 December 2013                               |
| Expiration Date ("Expiry")                   | Open End                                        |
| Maturity Date / Redemption Date               | means the 5th Business Day following the Effective Exercise Date. In case this date is not a Business Day the next following Business Day will apply (subject to Market Disruption Event provisions). |

Contact: UBS AG, P.O. Box, 8098 Zürich
Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com
Internet: www.ubs.com/keyinvest
Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.
Redemption

The Investor is entitled to receive from the Issuer on the Redemption Date an amount in the Settlement Currency, according to the following formula and taking into account the Conversion Ratio:

\[ \text{Expiration Value} \times \prod_{t=1}^{T} \left(1 - \frac{\text{MF}_t}{360} \right) \]

\( T \) = the number of calendar days that have passed since the Pricing Date. The Management Fee is deducted daily and in arrears (each a “Risk Management Fee Calculation Date”).

Management Fee (MF_t) = The level of the Management Fee, if any, on day t after the Pricing Date. The Management Fee will be determined at the reasonable discretion of the Calculation Agent and as per provisions set out under Management Fee Adjustment.

Expiration Value = Official closing value of the Underlying on the Effective Exercise Date on the Related Exchange, as determined by the Index Sponsor(s).

Product Structure

The UBS-ETT (Exchange Traded Tracker) allows for participation in the performance of the Underlying (converted by the Conversion Ratio).

General Information

Issuer: UBS AG, London Branch
Issuer Rating: A2 Moody’s / A S&P’s / A Fitch
Lead Manager: UBS AG, Zurich (UBS Investment Bank) / UBS Limited
Calculation Agent: UBS AG, London Branch
Paying Agent: UBS AG, Zurich
Listing: SIX Swiss Exchange listing will be applied for
Index Sponsor: Russell Investment Group
Related Exchange: The stock exchanges on which securities comprising the Underlying Index are traded, as determined by the Index Sponsor from time to time.
Secondary Market: Daily price indications will be available on Reuters/Bloomberg, www.ubs.com/keyinvest and Telekurs from 09:15-17:15 CET.
Minimum Investment: 1 Unit(s) (subject to Selling Restrictions)
Minimum Trading Lot: 1 Unit(s)
Status: Unsecured / Unsubordinated
Clearing: SIX SIS, Euroclear, Clearstream (registered as intermediated securities with SIX SIS AG, in Switzerland)
Form of deed: Uncertificated securities
Governing Law / Jurisdiction: Swiss / Zurich
Product: One USD-denominated UBS-ETT unit is equivalent to one (1) “Product”. “Products” wherever used herein shall be construed to mean integral multiples of the same, subject to the issue size.
Public Offering: Switzerland

Contact: UBS AG, P.O. Box, 8098 Zürich
Internet: www.ubs.com/keyinvest
Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com
Product Hotline: +41-44-239 76 76 *

Investors outside of Switzerland should consult their local client advisors. Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.
### Management Fee Adjustment
The Issuer has the annual right, on 31 December, for the first time on 31 December 2014 (“Fee Adjustment Notice Date”) to adjust the Management Fee effective 13 months after the “Fee Adjustment Notice Date” has been published to that effect (in case that any of the dates is not an Exchange Business Day, the next following Exchange Business Day applies).

### Management Fee Adjustment Date
Means the day when the Management Fee Adjustment becomes effective (corresponds to 13 months after the “Fee Adjustment Notice Date” subject to Market Disruption Event provisions).

### Issuer Call Right
The Issuer has the right to call the UBS-ETT for early redemption by giving notice to that effect. The UBS-ETT can be terminated at any time by communicating the Termination Date. The termination becomes effective after a notice period of 6 months, for the value equal to Redemption (as described herein) at the Effective Exercise Date (in case that any of the dates is not a Business Day, the next following Business Day applies). Subject to Market Disruption Event provisions the UBS-ETT will be redeemed on the Redemption Date.

### Investor Exercise Right
In addition to the possibility to sell the UBS-ETT at any time in the Secondary Market (subject to market conditions), each Investor has an annual right, on 31 January for the first time on 31 January 2015 (“Exercise Date”), to exercise the UBS-ETT (notice to be received not later than 10 am CET on the relevant Exercise Date) for a value equal to Redemption (as described herein) 1 year after the “Exercise Date” (“Effective Exercise Date”). The exercise will become effective as of close of business 1 year after the relevant Exercise Date (in case that any of the dates is not an Exchange Business Day, the next following Exchange Business Day applies). Subject to Market Disruption Event provisions the UBS-ETT will be redeemed on the Redemption Date.

### Effective Exercise Date
Means the day when either the Issuer’s Call Right or the Investor’s Exercise Right becomes effective (corresponds to 1 year after the “Exercise Date” in case of investor’s exercise and to 6 months after the “Termination Date” in case of issuer’s call and subject to Market Disruption Event provisions).

### Tax Treatment Switzerland

<table>
<thead>
<tr>
<th>Tax Treatment</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Swiss Federal Stamp Duty</strong></td>
<td>Secondary market transactions are not subject to Swiss Stamp Duty.</td>
</tr>
<tr>
<td><strong>Swiss Federal Income Tax</strong></td>
<td>For private investors resident in Switzerland who hold the product on the Closing Date, any kind of distribution reinvested in the index or basket (dividends, repayments of nominal value and capital contribution reserves) is subject to income tax on an annual basis. The amount will be determined and reported to the Swiss Federal Tax Administration annually for publication in the Kursliste (list of tax values). Closing date (for Swiss tax purposes): December 31, for the first time December 31, 2018.</td>
</tr>
<tr>
<td><strong>Swiss Withholding Tax</strong></td>
<td>The product is not subject to the Swiss withholding tax.</td>
</tr>
<tr>
<td><strong>EU Savings Tax Treatment</strong></td>
<td>For Swiss paying agents, the product is not subject to the EU Savings tax (TK9).</td>
</tr>
</tbody>
</table>

The tax information only provides a general overview over the Swiss tax consequences linked to this product based on the tax laws and the practice of the tax administration at the time of issue. Tax laws and the practice of tax administrations may change, possibly with retroactive effect.
Product Documentation

UBS Summary and Securities Note for the issue of Securities (registered with BaFin and EUPD compliant).

Final Terms

This document serves as and fulfils the requirements of a ‘Simplified Prospectus’ in accordance with Art. 5 of the Swiss Federal Act on Collective Investment Schemes (CISA). The Simplified Prospectus together with the UBS Summary and Securities Note for the issue of Securities (“SSC”), the Registration Document and the respective Final Terms shall form the documentation for this Product (“Product Documentation”), and accordingly the Simplified Prospectus should always be read in conjunction with these documents. The terms “Product” respectively “Investor” as used in this Simplified Prospectus correspond to the terms “Note”/“Certificate” respectively “Securityholder” as defined in the SSC.

During the whole term of this Product, the Product Documentation can be ordered free of charge from the Lead Manager at P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). In addition, for clients outside of the United Kingdom, the Product Documentation is available on the internet at www.ubs.com/keyinvest.

Notices in connection with this Product shall be validly given by publication in electronic media such as Reuters and/or Telekurs. In addition, any changes with regard to the terms of this Product shall be published on the internet at www.ubs.com/keyinvest.

Classification

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ff of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA (this paragraph is relevant to public offerings in Switzerland only).

Furthermore, this Product does not benefit from any depositor protection under Art. 37b under the Swiss Federal Law on Banks and Savings Banks (Banking Act) or other forms of deposit insurance under any other law as might be applicable to this Product.

Prudential Supervision

UBS AG is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). In addition, its London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority and its Jersey Branch is authorised and regulated by the Jersey Financial Services Commission (JFSC).

2. Prospects of Profits and Losses

Market Expectation

The UBS-ETT is a product for Investors who expect the Underlying to increase over the life of the Product.

Risk Tolerance

Investors in this product should be experienced investors and familiar with both derivative products and the stock markets.

The Investors must be willing to make an investment that is exposed to the full down-side risk of the Underlying.

The Investors do not require capital protection.

Profit Potential

The product allows full participation in the Underlying.

Loss Potential

The Investors may lose some or all of the investment as they are fully exposed to the performance of the Underlying.
3. Significant Risks for Investors

For product specific risks please see above (2. Prospects of Profits and Losses)

Risk Factors relating to the Issuer

In addition to the market risk with regard to the development of the Underlying, each Investor bears the general risk that the financial situation of the Issuer could deteriorate. The Products constitute immediate, unsecured and unsubordinated obligations of the Issuer, which, particularly in case of insolvency of the Issuer, rank pari passu with each and all other current and future unsecured and unsubordinated obligations of the Issuer, with the exception of those that have priority due to mandatory statutory provisions. The general assessment of the Issuer’s creditworthiness may affect the value of the Products. This assessment generally depends on the ratings assigned to the Issuer or its affiliated companies by rating agencies such as Moody’s, Fitch and Standard & Poor’s.

The Issuer Ratings indicated in this document reflect the situation at the time of issuance and may be subject to changes. The actual Issuer Ratings at any given time can be seen on the Issuer’s website (www.ubs.com) under “Analysts & Investors”.

Secondary Market

The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, to provide bid and offer prices for this Product on a regular basis. However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices. Potential Investors therefore should not rely on the ability to sell this Product at a specific time or at a specific price.

In special market situations, where the Issuer is completely unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer.

Market Risk

The investor is exposed to market disruption events (such as trading disruption, exchange disruption and early closure of the relevant exchange), adjustments and early termination which could have an impact on the redemption amount through delay in payment or change in value. For a detailed description of such events and their effects please read the Product Documentation.
Important Information

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which this document relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this document. UBS’ trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Products/Notes (the “Prospectus”).

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS' prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the Products described herein, save where explicitly stated in the Product Documentation. The Products must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

There is a possibility that costs, including taxes, related to transactions in connection with this Product may arise for the Investor that are not paid by UBS or imposed by it.

Index Disclaimer

The Russell 2000 Net TR Index is a trademark of Frank Russell Company and have been licensed by UBS. The Product(s) is/are not sponsored, endorsed, sold or promoted by Frank Russell Company and Frank Russell Company makes no representation regarding the advisability of investing in the Product.

The Product(s) is (are) not sponsored, endorsed, sold or promoted by Frank Russell Company („Russell”). Russell makes no representation or warranty, express or implied, to the owners of the Product(s) or any member of the public regarding the advisability of investing in securities generally or in the Product(s) particularly or the ability of the Russell 2000 Net TR Index to track general stock market performance or a segment of the same. Russell’s publication of the Russell 2000 Net TR Index in no way suggests or implies an opinion by Russell as to the advisability of investment in any or all of the securities upon which the Russell 2000 Net TR Index is based. Russell’s only relationship to UBS is the licensing of certain trademarks and trade names of Russell and of the Russell 2000 Net TR Index which is determined, composed and calculated by Russell without regards to UBS or the Product(s). Russell is not responsible for and have not reviewed the Product(s) nor any associated literature or publications and Russell makes no representation or warranty express or implied as to their accuracy or completeness, or otherwise. Russell reserves the right, at any time and without notice, to alter, amend, terminate or in any way change the Russell 2000 Net TR Index. Russell has no obligation or liability in connection with the administration, marketing or tradin of the Product(s).

RUSSELL DOES NOT GUARANTEE THE ACCURACY AND/OR THE COMPLETELESS OF THE RUSSELL 2000 NET TR INDEX OR ANY DATA INCLUDED THEREIN AND RUSSELL SHALL HAVE NO LIABILITY FOR ANY ERRORS, OMISSIONS, OR INTERRUPTIONS THEREIN. RUSSELL MAKES NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY UBS, INVESTORS, OWNERS OF THE PRODUCT(S), OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE RUSSELL 2000 NET TR INDEX OR ANY DATA INCLUDED THEREIN. RUSSELL MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE RUSSELL 2000 NET TR INDEX OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL RUSSELL HAVE ANY LIABILITY FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

Contact: UBS AG, P.O. Box, 8098 Zürich
Internet: www.ubs.com/keyinvest
Private Investors: Please contact your client advisor or send an email to keyinvest@ubs.com
Product Hotline: +41-44-239 76 76*

Investors outside of Switzerland should consult their local client advisors.
Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.
Selling Restrictions

Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.

The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.

Europe - Any public offer of this Product within a EEA jurisdiction (EU member states plus Norway, Iceland and Liechtenstein) shall only be possible if compliant with the requirements of the EUPD and with the law of that jurisdiction.

If the prospectus either does not qualify as a prospectus published in accordance with the requirements of the EUPD or is not filed with or notified to the relevant Financial Supervisory Authority, this Product may not be offered or sold in EEA jurisdictions other than:

1) in minimum denominations of, or total consideration per investor of at least, EUR 50,000 (or equivalent in other currencies), provided that the offer is only being made in one or more EEA jurisdictions that will not, before the end of the offer period for the Securities, have implemented the provision under the Directive 2010/73/EU (the “PD Amending Directive”) that increases this minimum denomination (or total consideration per investor) to EUR 100,000; or
2) only to Qualified Investors, and/or (aggregated for all distributors) to less than 100 or, if the relevant EEA jurisdiction has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal persons that are not Qualified Investors per EEA jurisdiction. “Qualified Investors” are persons or entities as defined in the Prospectus Directive.

For information on public offering in EEA jurisdictions please see under section “General Information” above.

Hong Kong – Each purchaser has represented and agreed that it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the Products, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Products which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.

This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you are in any doubt about the risks involved in the product, you may clarify with the intermediary or seek independent professional advice.

Singapore - This Term Sheet, the Final Terms, the Base Prospectus and the Supplemental Prospectus in respect of the programme under which the Notes would be issued have not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this Term Sheet, the Final Terms, the Base Prospectus, the Supplemental Prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the Notes may not be circulated or distributed, nor may the Notes be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than:

(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, or
(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the Notes pursuant to an offer made under Section 275 of the SFA except:

1) to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;
2) where no consideration is or will be given for the transfer;
3) where the transfer is by operation of law;
4) as specified in Section 276(7) of the SFA; or
5) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.

UK – For the purpose of non-discretionary accounts, this Product should not be sold with a consideration of less than 100,000 EUR or equivalent.

USA - This Product may not be sold or offered within the United States or to U.S. persons.